
Arvinas Inc (ARVN) Stock Forecast & Price Target
Arvinas Inc (ARVN) Analyst Ratings
Bulls say
Arvinas Inc. has demonstrated significant increases in the valuations of several key product candidates, including ARV-102, ARV-393, and ARV-806, reflective of their advancing clinical development stages and potential market impact. The company's overall enterprise value has grown to $959 million from $627 million, indicating robust pipeline progress and investor confidence in its innovative protein degradation platform. Furthermore, the integration of promising clinical data, such as enhanced synergy in pan-KRAS degraders, underscores Arvinas's capacity to potentially lead in targeted therapies for oncology, reinforcing a favorable long-term outlook for the company’s stock.
Bears say
Arvinas Inc is experiencing a negative outlook primarily due to a substantial reduction in projected peak revenue for its product vepdegestrant from $641.2 million to $296.9 million, reflecting less favorable economic conditions and competitive pressures in the oncology market. Additionally, the company faces challenges in accessing capital, which could impede critical business functions and delay profitability and cash flow generation. Furthermore, the potential inability to defend its portfolio may result in a loss of market potential for its drug candidates, especially in an increasingly competitive landscape for oncology therapeutics.
This aggregate rating is based on analysts' research of Arvinas Inc and is not a guaranteed prediction by Public.com or investment advice.
Arvinas Inc (ARVN) Analyst Forecast & Price Prediction
Start investing in Arvinas Inc (ARVN)
Order type
Buy in
Order amount
Est. shares
0 shares